Sign in
Welcome! Log into your account
Forgot your password? Get helpPrivacy PolicyPassword recovery
Recover your password
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology NewsHomeSponsoredBreaking the Wet-Lab Bottleneck in AI-Driven Antibody Discovery
Credit: Sino Biological
Sponsored content brought to you by
As AI-driven innovation accelerates and antibody pipelines expand, wet-lab validation must keep pace with the speed and scale of computational discovery. Efficiently translating large numbers of antibody sequences into reliable experimental results requires high-throughput expression, parallelized testing, and structured data generation within an integrated workflow.
Sino Biological’s high-throughput antibody production and developability assessment platform is designed to meet this need. By integrating antibody production, developability profiling, and AI-ready data generation, the platform enables the parallel evaluation of thousands of antibody candidates within compressed timelines and can deliver high-quality data in as fast as three days.
This streamlined approach helps identify developability risks earlier, supports data-driven candidate evaluation and prioritization, and generates high-quality datasets for AI model training and iterative antibody optimization.
The role of high-throughput expression in AI design
As AI models become increasingly capable ofde novoantibody design, efficient expression is essential for translating computationally generated sequences into testable antibodies. Sino Biological’s high-throughput antibody production solution combines complementary mammalian and cell-free expression platforms to support diverse antibody formats and project requirements. This dual-platform approach enables rapid design–build–test–learn cycles, providing experimental feedback for candidate refinement and iterative AI model optimization.
Proven mammalian expression & rapid cell-free synthesis
Mammalian expression systems, particularly HEK293 and CHO cells, are well established for recombinant antibody production because they support proper folding and post-translational modifications. Drawing on extensive expertise in high-throughput gene synthesis, vector construction, and optimized HEK293 and CHO transient expression, Sino Biological supports the small-scale production of high-quality recombinant antibodies across multiple formats, including VHHs, scFvs, Fabs, IgGs, bispecific antibodies, chimeric antibodies, and Fc-fusion proteins—with over 100,000 projects delivered. This mammalian platform can process more than 1,000 antibodies per project, with a sequence-to-purified-antibody turnaround in as little as 10 days.
Cell-free protein synthesis (CFPS) offers a rapid and flexible alternative for projects requiring greater speed or involving sequences that are challenging to express in mammalian cells. By harnessing transcriptional and translational machinery outside living cells, CFPS produces proteins in a controllable, open reaction environment while eliminating time-consuming cell culture steps, making it well suited to rapid, high-throughput workflows. Sino Biological’s CFPS platform can complete expression in as fast as three hours, accelerating the conversion of AI-generated sequences into testable molecules, particularly for the ultra-fast screening of VHHs, scFvs, and mini-binders. Free from cellular viability constraints, CFPS also supports the production of toxic or difficult-to-express proteins and the incorporation of non-canonical amino acids, expanding the possibilities of AI-driven design.
De-risking antibody discovery through early developability assessment
Early-stage developability profiling is pivotal for de-risking the antibody discovery pipeline and streamlining candidate selection. Systematic antibody developability evaluation enables proactive identification and management of potential liabilities—for example, deprioritizing candidates with desirable binding characteristics but unfavorable biophysical properties.
Sino Biological provides comprehensive early-stage developability assessment, encompassing more than 20 ready-to-use assays to evaluate key attributes, including self-association (AC-SINS), hydrophobicity (HIC-HPLC/PAIA-HIC), thermal stability (nanoDSF/DSC), polyreactivity (BVP/DNA/insulin ELISA), and colloidal stability (SMAC-HPLC). Flexible assay selection and customization are available to meet specific project requirements. Sino Biological delivers structured, AI-ready datasets that provide a multidimensional view of antibody developability profiles, enabling early risk identification and accelerating AI-driven discovery workflows.
To Learn More, Visitsinobiological.com/services/htp-platform-for-ai-driven-antibody-discovery.
SponsoredAntibodies (Immune system)Artificial intelligenceHigh throughput screeningProteinsRecombinant productSino BiologicalAlso of Interest
CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving MicePD-L2 Blockade May Reduce Harmful Aging Cell BuildupChronic Interferon Exposure Linked to Immunosuppression in CancerManus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE ProgramSmarter Cell Culture Starts with Better MediaRevvity Signs Agreement to Acquire Human Cell DesignRelated Media
Data Integrity as the Foundation for AISmall Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and SustainabilityBeyond the Technology: AI Readiness in Regulated LaboratoriesAACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven EraReporting Live from JPM 2026: Alex Philippidis and Jonathan Grinstein, PhDAI in Protein Design: Hype vs. Reality Explained by David BakerCopyright © 2026 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
MORE STORIES
